Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2460996 | 0.75 | MAPT (0.37) | MEN1KMT2AALDH1A1LMNAMAPK1 | |
| SCHEMBL2460995 | 0.75 | MAPT (0.37) | MEN1KMT2AALDH1A1LMNAMAPK1 | |
| SCHEMBL2461357 | 0.72 | — | — | |
| (Z)-1,2-Diphenylethene SCHEMBL22712863 | 0.72 | MAOB (0.73) | CYP11B1CYP11B2MEN1KMT2AMAOB | |
| (Z)-1,2-Diphenylethene SCHEMBL9134305 | 0.72 | MAOB (0.73) | CYP11B1CYP11B2MEN1KMT2AMAOB | |
| (Z)-1,2-Diphenylethene SCHEMBL443 | 0.72 | MAOB (0.73) | CYP11B1CYP11B2MEN1KMT2AMAOB | |
| (Z)-1,2-Diphenylethene SCHEMBL347707 | 0.72 | MAOB (0.73) | CYP11B1CYP11B2MEN1KMT2AMAOB | |
| (Z)-1,2-Diphenylethene SCHEMBL21847984 | 0.72 | MAOB (0.73) | CYP11B1CYP11B2MEN1KMT2AMAOB | |
| (Z)-1,2-Diphenylethene SCHEMBL9488270 | 0.72 | MAOB (0.73) | CYP11B1CYP11B2MEN1KMT2AMAOB | |
| (Z)-1,2-Diphenylethene SCHEMBL9134296 | 0.72 | MAOB (0.73) | CYP11B1CYP11B2MEN1KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | Smilebiotek Zhuhai Limited (CN) | 2024-06-25 | — | — | US | disclosed |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | Smilebiotek Zhuhai Limited (CN) | 2024-06-25 | — | — | US | disclosed |
| US-20220016146-A1 | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION | Smilebiotek Zhuhai Limited (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20220015338-A1 | ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS | Smilebiotek Zhuhai Limited (CN) | 2022-01-20 | — | — | US | disclosed |
| WO-2020113373-A1 | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION | ZHUHAI QIWEI BIO-TECHNOLOGY LTD. (CN) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020113759-A1 | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION | ZHUHAI QIWEI BIO-TECHNOLOGY LTD. (CN) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020098630-A1 | ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS | ZHUHAI QIWEI BIO-TECHNOLOGY LTD. (CN) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016146-A1 | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION | AGER, CASP3, PDE6D | CYP11B1 1208/4885CYP11B2 1107/4885MEN1 2125/4885 |
| US-12016312-B2 | Animal models, screening methods, and treatment methods for intraocular diseases or disorders | MB, MYOC, PDE6A | CYP11B1 2284/4885CYP11B2 1925/4885MEN1 1097/4885 |
| US-20220015338-A1 | ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS | MB, MYOC, PDE6A | CYP11B1 2284/4885CYP11B2 1925/4885MEN1 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.